Targeted Muscle Reinnervation for Amputations

Phase-Based Progress Estimates
Banner - University Medical Center, Phoenix campus, Phoenix, AZ
Targeted Muscle Reinnervation - Procedure
All Sexes
What conditions do you have?

Study Summary

The purpose of this study is to examine the effect of targeted muscle reinnervation on the outcomes of amputees at a level 1 trauma center. The investigators propose to randomize all patients requiring amputation with and without targeted muscle reinnervation. This study will help delineate the efficacy of targeted muscle reinnervation in the general population.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Pre-operative through 24 months

Pre-operative through 24 months
Effect of TMR on neuroma
Effect of TMR on phantom limb pain

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Amputation without TMR (SOC)
1 of 2
Amputation with TMR
1 of 2
Active Control
Experimental Treatment

50 Total Participants · 2 Treatment Groups

Primary Treatment: Targeted Muscle Reinnervation · No Placebo Group · N/A

Amputation with TMR
Experimental Group · 1 Intervention: Targeted Muscle Reinnervation · Intervention Types: Procedure
Amputation without TMR (SOC)NoIntervention Group · 1 Intervention: Amputation without TMR (SOC) · Intervention Types:
First Studied
Drug Approval Stage
How many patients have taken this drug
Targeted Muscle Reinnervation

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: pre-operative through 24 months
Closest Location: Banner - University Medical Center, Phoenix campus · Phoenix, AZ
Photo of Phoenix 1Photo of Phoenix 2Photo of Phoenix 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Amputations
0 CompletedClinical Trials

Who is running the clinical trial?

Joshua HustedtLead Sponsor
Joshua Hustedt, MD, MHSPrincipal InvestigatorUniversity of Arizona

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.